利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

9 条记录 (耗时 0.029 秒)

    COMBINATION THERAPY
    2.
    发明申请
    COMBINATION THERAPY 有权
    组合治疗

    公开(公告)号：US20130273061A1

    公开(公告)日：2013-10-17

    申请号：US13799706

    申请日：2013-03-13

    申请人： Xizhong Huang ,  Malte Peters ,  Jennifer Lorraine Gansert ,  David Dong Eun Chang ,  Pedro Beltran

    发明人： Xizhong Huang ,  Malte Peters ,  Jennifer Lorraine Gansert ,  David Dong Eun Chang ,  Pedro Beltran

    IPC分类号： A61K39/395 ,  A61K31/4184

    CPC分类号： A61K39/3955 ,  A61K31/4184 ,  A61K2039/545 ,  C07K16/2863 ,  A61K2300/00

    摘要： The present invention relates to a pharmaceutical combination comprising a MEK inhibitor compound 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide or a pharmaceutically acceptable salt thereof and the IGF1R inhibitor ANTIBODY A, a pharmaceutical composition comprising such combination, methods for treating cancer comprising administration of a therapeutically effective amount of such combination to a subject in need thereof, and uses of such combination for the treatment of cancer.

    摘要翻译： 本发明涉及药物组合，其包含MEK抑制剂化合物6-（4-溴-2-氟苯基氨基）-7-氟-3-甲基-3H-苯并咪唑-5-甲酸（2-羟基乙氧基） - 酰胺或 其药学上可接受的盐和IGF1R抑制剂抗体A，包含这种组合的药物组合物，用于治疗癌症的方法，包括向有需要的受试者施用治疗有效量的这种组合，以及这种组合用于治疗癌症的用途。

    COMBINATION THERAPIES
    4.
    发明申请
    COMBINATION THERAPIES 审中-公开

    公开(公告)号：US20170296659A1

    公开(公告)日：2017-10-19

    申请号：US15510355

    申请日：2015-09-11

    申请人： David Lebwohl ,  Malte Peters ,  Novartis AG

    发明人： David Lebwohl ,  Malte Peters

    IPC分类号： A61K39/395 ,  C07K16/28

    摘要： Disclosed is a combination comprising an immunomodulator and a second therapeutic agent for use in treating cancer, wherein the immunomodulator is an inhibitor of an immune checkpoint molecule or an activator of a costimulatory molecule, or a combination thereof; and the second therapeutic agent is chosen from one or more of: 1) a c-MET inhibitor; 2) a CDK4/6 inhibitor; 3) a PI3K inhibitor; 4) a BRAF inhibitor; 5) an FGFR inhibitor; 6) a MEK inhibitor, or 7) a BCR-ABL inhibitor. The combination therapies can be used to treat or prevent cancerous conditions and/or disorders.

    ANTI-EpCAM IMMUNOGLOBULINS
    6.
    发明申请
    ANTI-EpCAM IMMUNOGLOBULINS 审中-公开
    抗EpCAM免疫球蛋白

    公开(公告)号：US20120294873A1

    公开(公告)日：2012-11-22

    申请号：US13486749

    申请日：2012-06-01

    申请人： Malte Peters ,  Mathias Locher ,  Nadja Prang ,  Cornelia Quadt

    发明人： Malte Peters ,  Mathias Locher ,  Nadja Prang ,  Cornelia Quadt

    IPC分类号： A61K39/395 ,  C07K16/30 ,  A61P35/00

    CPC分类号： C07K16/30 ,  A61K2039/505 ,  C07K2317/21

    摘要： The invention relates inter alia to a method of treating tumorous disease in a human patient by administering to the patient a human immunoglobulin specifically binding to the human EpCAM antigen, the immunoglobulin exhibiting a serum half-life of at least 15 days, the method comprising the step of administering the immunoglobulin no more frequently than once every week, preferably no more frequently than once every two weeks.

    摘要翻译： 本发明特别涉及通过向患者施用与人EpCAM抗原特异性结合的人免疫球蛋白，该免疫球蛋白的血清半衰期至少为15天，该方法包括： 每周施用免疫球蛋白的步骤不超过一次，优选不超过每两周一次。

    Anti-EpCam Immunoglobulins
    7.
    发明申请
    Anti-EpCam Immunoglobulins 审中-公开
    抗EpCam免疫球蛋白

    公开(公告)号：US20070274982A1

    公开(公告)日：2007-11-29

    申请号：US10589450

    申请日：2005-02-09

    申请人： Malte Peters ,  Mathias Locher ,  Nadja Prang ,  Cornelia Quadt

    发明人： Malte Peters ,  Mathias Locher ,  Nadja Prang ,  Cornelia Quadt

    IPC分类号： A61K39/395 ,  A61P35/00 ,  C07K16/30

    CPC分类号： C07K16/30 ,  A61K2039/505 ,  C07K2317/21

    摘要： The invention relates inter alia to a method of treating tumorous disease in a human patient by administering to the patient a human immunoglobulin specifically binding to the human EpCAM antigen, the immunoglobulin exhibiting a serum half-life of at least 15 days, the method comprising the step of administering the immunoglobulin no more frequently than once every week, preferably no more frequently than once every two weeks.

    摘要翻译： 本发明特别涉及通过向患者施用与人EpCAM抗原特异性结合的人免疫球蛋白，该免疫球蛋白的血清半衰期至少为15天，该方法包括： 每周施用免疫球蛋白的步骤不超过一次，优选不超过每两周一次。

    Anti-EpCAM immunoglobulins
    8.
    发明申请
    Anti-EpCAM immunoglobulins 审中-公开
    抗EpCAM免疫球蛋白

    公开(公告)号：US20050180979A1

    公开(公告)日：2005-08-18

    申请号：US10778915

    申请日：2004-02-13

    申请人： Malte Peters ,  Mathias Locher ,  Nadja Prang ,  Cornelia Quadt

    发明人： Malte Peters ,  Mathias Locher ,  Nadja Prang ,  Cornelia Quadt

    IPC分类号： C07K16/30 ,  G01N33/574 ,  A61K39/395

    CPC分类号： C07K16/30 ,  A61K2039/505 ,  C07K2317/21

    摘要： The invention relates inter alia to a method of treating tumorous disease in a human patient by administering to the patient a human immunoglobulin specifically binding to the human EpCAM antigen, the immunoglobulin exhibiting a serum half-life of at least 15 days, the method comprising the step of administering the immunoglobulin no more frequently than once every week, preferably no more frequently than once every two weeks.

    摘要翻译： 本发明特别涉及通过向患者施用与人EpCAM抗原特异性结合的人免疫球蛋白，该免疫球蛋白的血清半衰期至少为15天，该方法包括： 每周施用免疫球蛋白的步骤不超过一次，优选不超过每两周一次。